

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
09 December 2021 (09.12.2021)



(10) International Publication Number
WO 2021/245240 A1

(51) International Patent Classification:

C07K 14/705 (2006.01) C12N 5/10 (2006.01)

(21) International Application Number:

PCT/EP2021/065020

(22) International Filing Date:

04 June 2021 (04.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20178414.7	05 June 2020 (05.06.2020)	EP
20178721.5	08 June 2020 (08.06.2020)	EP

(71) Applicant: **PIERIS PHARMACEUTICALS GMBH**
[DE/DE]; Zeppelinstrasse 3, 85399 Hallbergmoos (DE).

(72) Inventors: **PEPER-GABRIEL, Janet**; c/o Pieris Pharmaceuticals GmbH, Zeppelinstrasse 3, 85399 Hallbergmoos (DE). **PRASSLER, Josef**; c/o Pieris Pharmaceuticals GmbH, Zeppelinstrasse 3, 85399 Hallbergmoos (DE). **EICHNER, Timo**; c/o Pieris Pharmaceuticals GmbH, Zeppelinstrasse 3, 85399 Hallbergmoos (DE). **GRUENER, Stefan**; c/o Pieris Pharmaceuticals GmbH, Zeppelinstrasse 3, 85399 Hallbergmoos (DE). **MOUSA, Ahmed**; c/o Pieris Pharmaceuticals GmbH, Zeppelinstrasse 3, 85399 Hallbergmoos (DE). **OLWILL, Shane**; c/o Pieris Pharmaceuticals GmbH, Zeppelinstrasse 3, 85399 Hallbergmoos (DE).

(74) Agent: **SCHIWECK, Wolfram** et al.; Schiweck Weinzierl Koch, Patentanwälte, Ganghoferstrasse 68b, 80339 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MULTIMERIC IMMUNOMODULATOR TARGETING 4-1BB

(57) Abstract: The disclosure provides multimeric proteins comprising three, four, or more monomer polypeptides, each comprising a first 4-1BB-targeting moiety, an oligomerization moiety, and optionally a linker. The monomer polypeptide may further comprise one or more additional targeting moieties. The oligomerization moiety promotes the trimerization, tetramerization, or higher state of oligomerization of the monomer polypeptides. Such multimeric proteins can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators. The present disclosure also concerns methods of making the multimeric proteins described herein as well as compositions comprising such multimeric proteins. The present disclosure further relates to nucleic acid molecules encoding such multimeric proteins and methods for the generation of such multimeric proteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such multimeric proteins as well as compositions comprising one or more of such multimeric proteins.



WO 2021/245240 A1